BeiGene Change in Accounts Payable 2014-2024 | ONC

BeiGene annual/quarterly change in accounts payable history and growth rate from 2014 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
  • BeiGene change in accounts payable for the quarter ending September 30, 2024 was $0.014B, a 56.84% decline year-over-year.
  • BeiGene change in accounts payable for the twelve months ending September 30, 2024 was $0.084B, a 395.59% decline year-over-year.
  • BeiGene annual change in accounts payable for 2023 was $0.021B, a 593.66% decline from 2022.
  • BeiGene annual change in accounts payable for 2022 was $-0.004B, a 121.75% decline from 2021.
  • BeiGene annual change in accounts payable for 2021 was $0.02B, a 79.12% decline from 2020.
BeiGene Annual Change in Accounts Payable
(Millions of US $)
2023 $21
2022 $-4
2021 $20
2020 $96
2019 $2
2018 $23
2017 $55
2016 $3
2015 $6
2014 $1
2013 $-1
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $17.962B $2.459B
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
Stock Name Country Market Cap PE Ratio
Heidelberg Materials AG (HDLMY) Germany $22.212B 0.00
BrightSphere Investment Group (AAMI) United States $0.962B 11.46
Viad Corp (PRSU) United States $0.883B 39.27
Westaim (WEDXD) Canada $0.461B 12.39
Coliseum Acquisition (RAIN) United States $0.040B 0.00
ILearningEngines (AILEQ) United States $0.000B 0.00